PT - JOURNAL ARTICLE AU - Elmageed Eltayeb, Elkhazin Ali Abd AU - Gameel, Fatelrhman Mahdi AU - Idris, Abeer Babiker AU - Dawoud, Enas dk. AU - Hamid Mukhtar, Hajir Sir Elkhatim AU - Mohieldein, Abdelmarouf Hassan AU - Mutlu, Mehmet Burak AU - Mohmmed Ali, Ismail A. Elrhman AU - Gassoum, Alsadig AU - Hassan, Mohamed A. TI - Identification of splicing defects caused by novel exonic mutations in <em>LEF1</em> in Sudanese B- chronic lymphocytic leukemia patients: computational approach AID - 10.1101/2022.07.18.22277759 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.18.22277759 4099 - http://medrxiv.org/content/early/2022/07/19/2022.07.18.22277759.short 4100 - http://medrxiv.org/content/early/2022/07/19/2022.07.18.22277759.full AB - Background Lymphocyte enhancer factor-1 (LEF-1) is a member of the LEF-1/TCF family of transcription factors that are critically involved in canonical Wnt/β-catenin Signaling to regulate B Lymphocyte proliferation and survival. Alteration of LEF1 expression and function leads to leukemogenesis as well as other several neoplasms.Aims to identify mutations in exons two and three of the LEF1 among B-CLL Sudanese patients. Also, to functionally analyze the detected SNPs using different in silico tools.Materials and methods Immuno-phenotype for the detection of B cells CD5 and CD19 markers was performed on 128 B-CLL Sudanese patients by using a flow cytometry technique. DNA extraction, conventional PCR, and Sanger sequencing were applied to the LEF1 gene. Also, we performed a mutational analysis for identified SNPs using bioinformatics tools.Results A positive CD5 &amp; CD19 expression was found in B-CLL patients. No mutation was observed in exon two. While four mutations were observed in exon three; two of them were not reported in previous studies. Interestingly, splicing analysis predicted that these mutations could lead to splicing defects in LEF1 pre-mRNA due to their potential effects on splicing regulatory elements (i.e. ESE).Conclusion the two mutations Pro134Pro and Ile135Asn (novel mutation) were detected in all enrolled CLL patients and they could be used as diagnostic and/or prognostic markers for CLL. Therefore, further in vitro and in vivo functional studies with a large sample size are required to verify the splicing effect of the detected mutations in LEF1 pre-mRNA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance was taken from the Ethical Review Board of the National Ribat University. Informed consent was obtained from each patient.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript